Alector, Inc.
No SEC Form 4 filings for $ALEC in the last 30 days.
See all $ALEC insider activity →Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.
Shionogi to acquire IntraBio for $2.0B, adding Aqneursa for rare diseases. Gate Bioscience expands Eli Lilly collaboration, potentially worth $870M. Alector licenses Al050 to Genentech for up to $1.27B, targeting Parkinson's disease.
Morgan Stanley raised its price target for Alector Inc. (ALEC) to $3.00 from $2.00, citing milestone credits for AL050. The stock trades at $1.99 with a $222M market cap. The firm adjusted R&D expenses and EPS estimates, with GAAP EPS forecasted as negative for 2026-2028. Alector partnered with Genentech for AL050, a Parkinson's therapy, but Mizuho maintained a $1.50 target. Analysts see no profitability this year.
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning ALEC (Alector, Inc.). Coverage has skewed bullish: 10 bullish, 1 neutral, and 0 bearish.
Recent ALEC coverage spans financial news, mergers & acquisitions and market movers.
Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.
Shionogi to acquire IntraBio for $2.0B, adding Aqneursa for rare diseases. Gate Bioscience expands Eli Lilly collaboration, potentially worth $870M. Alector licenses Al050 to Genentech for up to $1.27B, targeting Parkinson's disease.
Analyst upgrade and partnership suggest upside potential.
The rating and target suggest limited upside; price may face pressure toward the target.
Alector, Inc.'s average stock price target increased from $3.1 to $3.3, with a range of $1 to $6, according to 5 analysts. This implies a 66% upside from the Oct. 5 closing price. The consensus rating remains 'Hold' among 7 analysts.
AlphAI scores every news story that mentions ALEC with an AI model for sentiment and relevance, and aggregates insider trades from Alector, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.
2 min readShionogi to acquire IntraBio for $2.0B, adding Aqneursa for rare diseases. Gate Bioscience expands Eli Lilly collaboration, potentially worth $870M. Alector licenses Al050 to Genentech for up to $1.27B, targeting Parkinson's disease.
2 min readMorgan Stanley raised its price target for Alector Inc. (ALEC) to $3.00 from $2.00, citing milestone credits for AL050. The stock trades at $1.99 with a $222M market cap. The firm adjusted R&D expenses and EPS estimates, with GAAP EPS forecasted as negative for 2026-2028. Alector partnered with Genentech for AL050, a Parkinson's therapy, but Mizuho maintained a $1.50 target. Analysts see no profitability this year.
1 min readMizuho maintained a Neutral rating and $1.50 price target for Alector (ALEC) after its partnership with Genentech. ALEC trades at $1.99, with a $222M market cap. The deal involves AL050, a preclinical therapy for Parkinson's. ALEC reported an 83% revenue decline and $158M negative free cash flow over the past year. Mizuho sees potential in ALEC's blood-brain-barrier technology.
1 min readAlector, Inc.'s average stock price target increased from $3.1 to $3.3, with a range of $1 to $6, according to 5 analysts. This implies a 66% upside from the Oct. 5 closing price. The consensus rating remains 'Hold' among 7 analysts.
1 min readRoche will pay up to $1.27 billion to license Alector's experimental Parkinson's therapy, AL050. The deal includes a $100 million upfront payment and potential milestone payments. Alector's shares surged 72% in premarket trading. Roche's Genentech unit will handle development and commercialization, with Alector eligible for royalties.
2 min readAlector stock surged 55.2% in pre-market trading after a licensing deal with Genentech for AL050, a Parkinson's disease treatment. The deal includes a $100M upfront payment and up to $1.17B in milestones. Alector retains rights to its ABC platform. The company's CEO noted the deal extends its cash runway to 2029. The broader market showed minimal movement, indicating the surge was company-specific.
2 min readAlector licensed AL050 to Genentech for $100M upfront, with $1.17B in potential milestones, and secured IP from Spur Therapeutics for $15M plus revenue share. The deals aim to advance AL050 and monetize assets.
2 min readAlector (ALEC) licensed AL050, a GCase ERT for Parkinson’s and neurodegenerative diseases, to Genentech. Alector receives $100M upfront, up to $1.17B in milestones, and royalties. AL050 uses Alector’s ABC tech to cross the blood-brain barrier. Genentech handles development, while Alector retains ABC rights. Alector will use funds to advance its pipeline, including Alzheimer’s and Parkinson’s programs. A webinar on Oct 13 will discuss Alector’s wholly owned pipeline.
2 min readRosenthal Arnon (Chief Executive Officer) sold 72,606 shares of Alector, Inc. (ALEC) at $2.66 ($0.19M total) on 2026-09-03.
1 min read
